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Statement of translational relevance 
 
Hypoxia is a well known microenvironmental factor determining tumor behavior. Despite this 
knowledge, its influence is never taken into account in clinical practice. We looked at gene 
expression changes in colon cancer cells exposed to chronic hypoxia. The hypoxia induced 
expression pattern correlated with the clinical outcome of more than 200 colon cancer patients 
in published microarray data sets confirming the detrimental role of intratumoral hypoxia on 
prognosis. We further describe the development of a 6 gene Colon Cancer Hypoxia Score 
(CCHS) which was found prognostic in two additional patient cohorts. Its value was 
independent of other important variables such as disease stage, differentiation grade and 
vascular invasion. Moreover, the CCHS performed excellent in both fresh frozen as well as in 
paraffin embedded material.  
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Abstract  
 
Purpose – Hypoxia is considered a major microenvironmental factor influencing cancer 
behavior. Our aim was to develop a hypoxia-based gene score that could identify high and low 
risk within stage II and III colon cancer patients. 
Experimental design – Differential gene expression of CaCo-2 colon cancer cells cultured in 
chronic hypoxia versus normoxia was tested for correlation with prognostic variables in 
published microarray data sets. These data sets were further used to downsize and optimize a 
gene score, which was subsequently determined in paraffin embedded material of 126 patients 
with colon cancer treated in our center. 
Results – In the CaCo-2 cells, 923 genes with a 2-fold change and Limma corrected p≤0.0001 
were found differentially expressed in hypoxia versus normoxia. We identified 21 genes with 
prognostic value and overlapping in three different training sets and (n=224). With a fourth 
published data set (n=177), the six gene Colon Cancer Hypoxia Score (CCHS) was developed. 
Patients with low CCHS showed a significant better disease free survival at three years (77.3%) 
compared to high CCHS patients (46.4%) (Log rank, p=0.006). This was independently confirmed 
in an external patient cohort of 90 stage II patients (86.9% vs 52.2%, p=0.001). 
Conclusions – Hypoxia driven gene expression is associated with high recurrence rates in stage 
II and III colon cancer. A 6-gene score was found to be of independent prognostic value in these 
patients. Our findings require further validation and incorporation in the current knowledgee 
on molecular classification of colon cancer. 
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Manuscript 
 
Introduction 
 
In Western countries, colorectal cancer (CRC) is the third most common cancer in both men and 
women and the second leading cause of cancer-related death, accounting for approximately 
500.000 deaths annually (1). Tumor stage (American Joint Committee on Cancer - AJCC) at 
presentation is the main factor for therapeutic decisions and prognostic estimates. Patients 
with stage II disease generally undergo surgery only, whereas in stage III, adjuvant 
chemotherapy after resection of the affected bowel segment and attached lymph nodes is the 
preferred treatment option (2). However, data from historical trials shows that 60% of stage III 
patients do not recur following surgery only whereas 20% of stage II patients do have recurrent 
disease after resection (3, 4). These findings have led to an extensive search for prognostic 
markers that could classify CRC patients more accurately, reducing over- or undertreatment. 
The finding that stage II patients with a high degree of tumor microsatellite instability (MSI-H) 
are at very low risk of recurrence helps guiding treatment (5). Driven by the success of this 
approach in breast cancer (6), extensive research has led to the development of dozens of 
prognostic gene signatures for colon cancer (7). Although used by some oncologists, gene 
signatures are currently not approved by the FDA nor adopted by any CRC treatment guideline 
(8).  
In this study, the aim was to develop a robust prognostic gene score to improve the 
subclassification of stage II and III colon cancer patients using a mechanism based approach 
previously described for hepatocellular carcinoma (9). It is now recognized that 
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microenvironmental factors such as hypoxia play a role in tumor behavior. Exposed to low 
oxygen supplies cancer cells become more aggressive, invasive and resistant to therapy (10). 
In vitro, we identified the differentially expressed genes under chronic hypoxia versus 
normoxia. Using bioinformatics on 3 published sets of expression data with corresponding 
clinical information we could identify 21 genes, related to both hypoxia and prognosis. Further 
optimization of the model led to a Colon Cancer Hypoxia Score (CCHS) of 6 genes which we 
evaluated in formalin-fixed, paraffin-embedded (FFPE) tissue of our own patient cohort as well 
as in an external data set. 
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Methods 
 
Cell culture and RNA isolation 
Method details are described in the supplementary files. Briefly, as in vitro model we used the 
human adenocarcinoma cell line CaCo-2 (HTB-37; ATCC, Rockville, MD, USA). Cells were grown 
in a humidified incubator (Sanyo MCO-18M O2/CO2 incubator, Osaka, Japan) (5% CO2 at 37°C) 
in MEM medium (InVitrogen, Merelbeke, Belgium) supplemented with 10% fetal calf serum, 2 
mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 1 mM sodium pyruvate. 
For the determination of chronic hypoxia conditions by RT-PCR, cells were seeded in 25cm2 
culture flasks (106 cells/flask) that were placed in either 2% O2 or 20% O2 after 24h attachment. 
All culture conditions were performed in triplicate and cells were collected for RNA isolation at 
0, 10, 24, 48 and 72 hours.  
For microarray analysis, cells were seeded at 3x106 in 75 cm² tissue culture flasks (n=4) at 20% 
O2 and were grown until 70% confluence. After reaching near-confluence, 2 flasks were placed 
in a humidified incubator with hypoxic conditions (2% O2, 5% CO2 at 37°C) for 72 h, while two 
other flasks remained in normoxic conditions (20% O2).  
Cells were harvested after trypsin treatment and mixed with Trizol (InVitrogen). RNA was 
isolated with the RNeasy Kit (Qiagen, Chatsworth, CA) according to the manufacturer’s 
instructions. 
 
RT-PCR 
RNA was reverse transcribed into cDNA using SuperScript II reverse transcriptase and random 
hexamer primers (InVitrogen). The PCR reaction was carried out using TaqMan Universal PCR 
Master Mixture and Assays-on-DemandTM Gene Expression products (Applied Biosystems, 
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Foster City, California). The primers used are listed in supplementary table S1. Beta-2 
microglobulin was used as housekeeping gene. Real-time PCR amplification and data analysis 
were performed using the A7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, 
California). The ΔΔCt-method was used to determine relative gene expression levels. 
 
Microarray 
Samples were hybridized on dual color Agilent's Human Whole Genome Oligo Microarray (Cat# 
G4112F, Agilent, Diegem, Belgium) that contained 44k 60-mer oligonucleotide probes 
representing around 41 000 well-characterized human transcripts. Sample processing, quality 
control and microarray data analysis is described in detail in the supplementary methods. To 
identify the highly significant differentially expressed genes under chronic hypoxic conditions, 
probes with a 2-fold change and a corrected p-value below 0.0001 after multiple testing 
correction were selected (11). Results were confirmed by performing RT-PCR on selected genes. 
 
Correlation of the hypoxia gene expression pattern with prognosis in external data sets 
Biomarker development and evaluation was done following the REMARK guidelines for tumor 
marker studies (12). In order to determine the clinical relevance of the hypoxia gene expression 
pattern we compared our findings with published microarray data sets containing 
corresponding clinical information.  
We considered four data sets of colon carcinoma patients, published in Gene Expression 
Omnibus (GEO) (Table 1), all based on the GeneChip Human Genome U133 Plus 2.0 array from 
Affymetrix. In Jorissen et al., 63 microsatellite stable (MSS) and 11 unstable (MSI) colorectal 
cancer samples from the Royal Melbourne Hospital were investigated (13). In Aronow et al., 
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recurrence status was available for 100 colon cancer patients after exclusion of mucosa 
samples (14). 232 patients with colon cancer and known clinical outcome were included in the 
study by Smith et al. (15). This set was divided into 55 samples from Vanderbilt Medical Center 
(referred to as VMC) and 177 samples from the Moffitt Cancer Center (MCC). 
All data sets were independent of one another, except for the data set of Aronow et al., which 
shows partial overlap with MCC samples (own observations). For this reason, we used the data 
sets of Jorissen and Aronow and the VMC subset of Smith to determine the prognostic value of 
the hypoxia gene expression pattern with a global test by Goeman (16).  
Subsequently, overlap between the hypoxia gene expression pattern and the three data sets 
was used to downsize the number of genes (prognostic signature, see figure 1). 
The MCC subset of Smith was used to optimize this signature by backward regression analysis 
using SPSS package 19 (IBM, Armonk, New York). A probability of F with a p-value of 0.05 was 
set as the treshhold for entry and removal. This way, we selected those genes that contributed 
the most to the model and enriched them with a coefficient which describes the relative 
contribution of the gene. The obtained score was named the “Colon Cancer Hypoxia 
Score”(CCHS). 
 
Prospective evaluation of the Colon Cancer Hypoxia score 
The Leuven cohort – 162 patients with stage II or III colon cancer treated in our center between 
2004 and 2006 were selected to test the performance of the CCHS. Patients with missing clinical 
data, patients with rectal cancer and those who did not survive at least one month after surgery 
were excluded. For this study, we used two parallel slides of FFPE material per patient. The first 
slide was H&E stained, and the tumor tissue marked by a pathologist. Tumor was then 
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dissected from non-tumorous tissue on the second slide and subsequently deparaffinized. RNA 
was extracted using a modified RNeasy FFPE protocol (supplementary methods). 
Quantification, sizing and quality control was performed with the Bioanalyzer platform 
(Agilent). Only samples with at least 50% of RNA fragments longer than 200 bases were 
selected. Samples were analyzed for expression of selected genes by the nCounter technique 
(NanoString Technologies, Seattle, WA) which gives a direct read-out of transcripts without the 
use of enzymatic reactions (17). The used CodeSet is described in supplementary table S2. 
The Amsterdam cohort – The AMC-AJCCII-90 data set consists of gene expression data on fresh 
frozen tumor tissue of 90 stage II patients treated in the Academic Medical Center in 
Amsterdam between 1997 and 2006. The Affymetrix Human Genome U133 Plus 2.0 Array was 
used as microarray platform (GSE33113) (18). 
 
Statistics 
All data are presented as median with range. A p-value < 0.05 was considered significant. To 
determine an optimal cutoff value for our Colon Cancer Hypoxia Score, a receiver operating 
characteristic (ROC) curve was used. For the survival analysis, Kaplan-Meier survival curves and 
univariate and multivariate Cox proportional hazard ratio were used. All statistics were 
performed using SPSS package 19 (IBM). 
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Results 
 
Dynamics in gene expression in CaCo-2  
To investigate the dynamics of hypoxia related gene expression in our in vitro model and to 
determine the optimal timing for microarray analysis we performed RT-PCR at different time 
points for a set of 8 representative genes known to be responsive to hypoxia. Gene expression 
was tested at 0 h, 10 h, 24 h, 48 h and 72 h in hypoxia (2% O2) versus normoxia. It should be 
noted that when CaCo-2 cells were kept beyond 72 hours their cultures tended to become 
super-confluent with partly detachment of the cells resulting in an uncontrolled fluctuation of 
the gene expression levels (data not shown). Most of the mRNA expression levels investigated 
showed a dynamic curve over time at 2% O2 with exception of BCL2 that did not change 
significantly at any of the time points investigated (supplementary figure S1). These 
observations support the assumption that the acute hypoxic state (up to 24 h) has a different 
gene expression pattern compared to the more chronic state (72 hours). As such, we chose the 
latter condition for our microarray experiment. 
 
Microarray: primary data analysis and development of a Colon Cancer Hypoxia Score 
Using Agilent technology, in CaCo-2 cells cultured for 72 hours at either 20% oxygen or in 
hypoxic conditions at 2% oxygen a total of 37,707 spots showed a representative signal of 
which 3,389 with a 2log fold change >1 or <-1 and a Limma corrected p-value <0.05. These 
microarray data are available at NCBI under number GSE31079.  
For the development of our gene signature, we started with the top 923 differentially 
expressed genes (with a 2log fold change >1 or <-1 and a Limma corrected p-value <0.0001): the 
hypoxia gene expression pattern. Of those 923 genes, 704 were up-regulated and 219 down-
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regulated in hypoxic conditions. The top altered genes and significant KEGG pathways involved 
are listed in supplementary table S3-S4. 
Subsequently, the Goeman global test showed that the overall expression pattern of these 
hypoxia genes was significantly related to the prognostic factor considered for each of the three 
training data sets (p-value <0.0001 for Jorissen, p-value = 0.00028 for Aronow and p-value = 
0.0107 for Smith VMC). 
Next, when only keeping the significant genes with a z-score above 1, 530 genes remained for 
the data set of Jorissen, 360 genes for Aronow, and 338 genes for Smith VMC. Finally, genes for 
which the direction of altered expression did not correspond to the direction observed in vivo 
in at least 2 out of 3 data sets were removed. With this approach, we were able to downsize the 
number of genes to twenty-one, found to overlap between the three training data sets (figure 
1). In this gene set of 21 genes, 17 genes were upregulated in hypoxic conditions and 4 were 
downregulated (table 2).  
 
CaCo-2 cells contain a TP53 mutation resulting in undetectable p53 protein levels (19). As such, 
TP53 was not considered early in the development of our gene signature despite being clinically 
of potential prognostic importance in colon cancer (20). For these reasons, TP53 was added 
afterwards to the in vitro-derived 21 hypoxia cancer genes. 
Using a backward linear regression analysis with the 21 genes and TP53 as independent 
variables and the AJCC disease stage of patients in a fourth data set (Smith MCC) as dependent 
variable, six genes showed the highest contribution to the model. These genes with their 
corresponding coefficient form the Colon Cancer Hypoxia Score (figure 1). The score consists of 
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the expression value of BCCIP, GADD45B, INSIG2, BNIP3L, MPHOSPH6 and TP53. The latter 
three have an inverse effect on the score value. All genes are involved in processes related to 
cell cycle, apoptosis and DNA repair. 
 
Prospective evaluation of CCHS 
Of the 162 stage II/III patients treated in our center between 2004 and 2006, 129 were selected 
for nCounter analysis after exclusion of clinical abberant cases and quality control (figure 2). 
Gene expression level of the CCHS genes was successfully obtained in 126 samples (97.7%). The 
known clinical and pathological features of these patients are summarized in table 3. Estimated 
median disease free survival times were 66.2 months (95% CI 60 – 71.5) and 46 months (95% CI 
37.5 – 54.5) for stage II and stage III patients, respectively. 
 
Using an optimal cut-off (see supplementary figure S2), patients with a low CCHS showed to 
have significant better disease free survival (DFS) at three years  compared to those with a high 
CCHS (77.3% vs 46.4% respectively, p=0.006). These DFS rates remained unchanged at five 
years. Median disease free survival was 62,2 months (95% CI 56.6-67.7) and 42.7 months (95% 
CI 33.4 – 52) for CCHS low and CCHS high patients respectively (p=0.006) (figure 3a). Patients 
with a favorable CCHS were more likely to be alive at three years (estimated overall survival 
81.5% vs 66.6%, p = 0.044) and at five years (71.9% vs 59.1%, p = 0.036). 
When disease AJCC stage was taken into account, survival analysis could identify three groups 
with significant difference in survival (figure 3b). Patients with stage II disease and unfavorable 
CCHS had almost similar disease behavior as stage III patients with a good (low) Colon Cancer 
Hypoxia Score. Moreover, the CCHS could identify a subgroup of stage III patients with an 
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estimated recurrence rate at three years of 75% and a median disease free survival of only 28.2 
months (95% CI 16 – 40.4).  
The characteristics of the 90 patients of the Amsterdam cohort are listed in table 3. Estimated 
disease free survival time for the whole cohort was 95.5 months (95% CI 85.8 – 105.2). Similar 
to the Leuven patient cohort, the CCHS identified two subgroups of stage II patients with 
different DFS at three years (86.9% vs 52.2%, p < 0.001) and five years (86.9% vs 52.2%, p < 
0.001). Median disease free survival was 102.5 months (95% CI 93.1 – 111.9) vs. 55.4 months 
(95% CI 38.7 – 72) (p=0.001) (figure 3c). Hazard ratio for recurrence in CCHS high versus CCHS 
low patients was 3.970 (95% CI 1.6 – 9.8) (p = 0.004). 
Subsequently, a univariate Cox regression analysis was performed on the Leuven cohort 
analyzing all known clinical and pathological variables. Four variables with significant prognostic 
value were included in a multivariate analysis. The multivariate Cox regression model confirmed 
that the Colon Cancer Hypoxia Score is a predictor for recurrence independent of disease stage, 
venous invasion and the number of examined lymph nodes (table 4). 
 
Discussion 
 
Colon cancer is associated with high morbidity and mortality and prognostic subclassification of 
stage II and III patients remains an ongoing clinical challenge. We describe the development 
and testing of a mechanism based prognostic gene score. Hypoxia as microenvironmental 
factor is well known for its influence on cancer behavior. If hypoxia does not induce cell death, 
it increases tumor aggressiveness, invasiveness and metastatic potential mainly through 
activation of the hypoxia-inducible factor (HIF) pathway (10). Despite this knowledge, hypoxia is 
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seldom taken into account in the clinical setting in part due to the lack of good endogenous 
hypoxia markers (21). HIF overexpression has been proven associated with prognosis, but HIF 
itself is not considered to be a hypoxia marker exclusively due to the fact that it can be 
activated in various settings including oncogene drive (22). Our method shows a correlation 
between the altered expression of hundreds of genes under hypoxic conditions in vitro, with 
that of tumors in published microarray data sets with clinical data available. This confirms the 
role of intratumoral hypoxia in disease behavior as was previously shown in HCC (9). 
Colon cancer is subject to extensive global scientific research and many gene signatures and 
scores have been developed in the past mostly based on hierarchical clustering. Some of these 
signatures have made it to commercially available tests. Although a promising approach to 
capture the complexity of cancer biology, few signatures show good power in external patient 
cohorts (7). We tried to address these limitations by using a mechanism-driven approach and 
involving different data sets in the development of our signature. This resulted in a workable 
amount of genes derived from data of over 400 patient samples. Moreover, we hypothesized 
that the optimization process with a backward regression model has added power to the 
prognostic value of the genes. 
p53 is a known important tumor suppressor in colon cancer and its pathway is modulated by 
hypoxia (23). This is further supported by our findings that, in vitro under hypoxic conditions, 
the p53 pathway is a highly significant altered KEGG pathway (supplementary table S4 and 
figure S3). For this reason and those stated above, TP53 was appended to the gene list in the 
knowledge that the backward regression analysis would eliminate this gene immediately in the 
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absence of an added value to the model. The fact that it was withheld in the CCHS suggests that 
TP53 gene expression is of prognostic value for colon cancer patients. 
Evaluation of the CCHS was done in formalin-fixed paraffin-embedded material. For mRNA level 
measurements, this type of material often presents a challenge as it is subjected to RNA 
degradation. After strict quality control (figure 2), the nCounter platform showed excellent 
performance and reliability for determining the expression levels of all 6 CCHS genes. 
Independent of other clinical and pathological parameters, the CCHS was found to predict 
relapse in stage II and III colon cancer. In stage II patients, it identified a high risk subgroup that 
might benefit from adjuvant therapy. Furthermore, stage III patients with unfavorable CCHS 
suffer from high recurrence rates. 
Recently, progress has been made in the field of molecular classification of colon cancer based 
on gene expression clustering, epigenetic markers and therapy response. This approach led to 
the proposition of 3 to 6 CRC subtypes (18, 24, 25). De Sousa et al identified two classes which 
seem to represent the known subgroups of MSI/CIMP and chromosomal-instable (CIN) tumors 
respectively (18). A third class, previously unidentified and related to serrated polyps, was 
associated with a poor prognosis. Tumors of this subgroup have stemness features, which is in 
line with others who have isolated a stem cell or epithelial-to-mesenchymal transition (EMT) 
associated subgroup of colon cancer patients with high recurrence rates (24-26). We see a 
striking overlap between the KEGG pathways involved in adapting to hypoxic conditions and 
those pathways attributed to the stem cell-like phenotype proposed by Marisa et al (25) 
(supplementary table S4). Further prospective validation in a larger patient cohort is needed to 
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clarify whether a high CCHS is indicative for the stemness subtype. If so, the limited number of 
genes together with the performance in FFPE samples render our CCHS a potential clinical tool.  
This study has some limitations. Unfortunately, at the time of study onset, extensive clinical 
data were not available for some of the published data sets used for CCHS development. This 
forced us to use surrogate parameters such as microsatellite instability which could influence 
the power of the obtained score. During study design, after careful evaluation of the available 
information, considerable overlap between different data sets published in the Gene 
Expression Omnibus was noticed. For example: most samples of the data set provided by 
Aronow et al. (GSE5206) have also been included in both GSE14333 and GSE17536 (own 
observations). This requires great caution when designing studies with this widely used 
published data. In our case, we compared the individual patient data of the data sets and found 
that there was a partial overlap between the database by Aronow and Smith MCC. In our study 
design, the latter was only involved in optimization of the gene signature and this overlap 
should therefore not affect our conclusions.  
When testing the performance of the CCHS we excluded rectal cancer. Despite the obvious 
similarities between colon and rectal cancer, we wanted to exclude the differences in 
treatment modalities as a confounder. As such, our results cannot be extrapolated to these 
patients. 
Finally, our study was designed to evaluate the CCHS as a prognostic marker. Further research is 
needed to determine whether the score has predictive abilities, ie. potency to identify patients 
likely to benefit from adjuvant treatment. 
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In conclusion, we discovered that the gene expression pattern of CaCo-2 cells cultured in 
hypoxia shows good correlation with clinical parameters of colon cancer patients in published 
microarray data sets. This confirms the importance of intratumoral hypoxia in disease behavior. 
From this point, a 6 gene Colon Cancer Hypoxia Score was developed which proved to be an 
independent prognostic biomarker for relapse in stage II and III colon cancer. 
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Legends to tables and figures 
 
Table 1: Clinical overview of published microarray data sets used for global performance testing 
of the hypoxia expression pattern and for development and optimization of the Colon Cancer 
Hypoxia Score. 
Abbreviations: NA, not available – MSS, microsatellite stable – MSI, microsatellite instable 
 
Table 2: Overview of the 21 gene signature with their relative direction in vitro under hypoxia 
and cellular processes involved. TP53 was added to the signature and eventually incorporated 
in the CCHS. 
Abbreviations: CCHS, colon cancer hypoxia score 
 
Table 3: Clinical and pathological features of the Leuven cohort as well as the AMC-AJCCII-90 
data set (16). Abbreviations: NA, not available – Median FU, median follow-up defined as time 
to relapse or last contact. 
 
Table 4: Univariate and multivariate Cox regression analysis on all clinical and pathological 
variables in the Leuven cohort. The Colon Cancer Hypoxia Score (CCHS) is an independent 
predictor of disease recurrence. 
Abbreviations: CI, Confidence Interval 
 
Figure 1: Process to obtain the Colon Cancer Hypoxia Score. Overlap between three published 
data sets and the hypoxia gene expression pattern in CaCo-2 cells was used to downsize the 
 21 
 
number of genes to 21. After adding TP53, a backward regression analysis was performed to 
obtain a six gene score. 
 
Figure 2: Inclusion and selection process of the stage II/III colon cancer patients in our center. 
Of the 162 colon cancer patients included in this study, after clinical and technical selection, the 
expression levels of 126 patients was successfully determined. 
 
Figure 3a: Kaplan-Meier curve for disease free survival in the Leuven cohort (n = 126).  
 
Figure 3b: AJCC disease stage and Colon Cancer Hypoxia Score (CCHS) devide patients in three 
groups with significant differences in disease free survival. When the patients of AJCC Patients 
with stage II disease and a high CCHS have comparable outcome to patients with stage III 
disease and a low CCHS. 
 
Figure 3c: Kaplan-Meier curve for disease free survival in the Amsterdam cohort (n = 90). 
Table 1
Author Jorissen Aronow
Reference 13 14
VMC database MCC database
Data set ID GSE13294 GSE5206 GSE17537 GSE17536
Used for Training signature Training signature Training signature Developing score
Array type
Sample type Fresh frozen Fresh frozen Fresh frozen Fresh frozen
N samples 74 105 55 177
N Colon cancer 74 100 55 177
Rectal cancer included Yes Yes Yes Yes
N other 5 normal mucosa
Age (median) (yrs) NA 66 62 66
   Min 26 23 26
   Max 92 94 92
Sex (M/F) NA
   Male 46 (46%) 26 (47%) 96 (54%)
   Female 54 (54%) 29 (53%) 81 (46%)
AJCC stage NA
   I 15 (15%) 4 (7%) 24 (14%)
   II 29 (29%) 15 (27%) 57 (32%)
   III 33 (33%) 19 (35%) 57 (32%)
   IV 20 (20%) 17 (31%) 39 (22%)
   NA 3 (3%) 0 0
Differentiation NA
   Good 8 (8%) 1 (2%) 16 (9%)
   Moderate 78 (78%) 32 (58%) 134 (76%)
   Poor 10 (10%) 3 (5%) 27 (15%)
   NA 4 (4%) 19 (35%) 0
Recurrence NA
   Yes 23 (23%) 19 (34%) 36 (24%)
   No 77 (77%) 36 (66%) 109 (62%)
   NA 32 (18%)
Median FU (months) NA NA 50.2 42.3
Affymetrix Human Genome U133 Plus 2.0 Array
Smith
15
   Min 0.4 0.9
   Max 111 142.5
Microsatellite instability NA NA NA
   MSS 63 (85%)
   MSI 11 (15%)
Table 2
Official gene symbol Direction In vitro Gene name Processes involved
BCCIP ▼ BRCA2 and CDKN1A-interacting protein isoform C DNA metabolic / repair
BNIP3L ▲ BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like apoptosis
BTBD14A ▲ nucleus accumbens-associated protein 2 unknown
DDIT4 ▲ DNA damage-inducible transcript 4 protein apoptosis / hypoxia
ERRFI1 ▲ ERBB receptor feedback inhibitor 1 GTPase regulation
FAM46C    ▼  hypothetical protein LOC54855 unknown
GADD45B   ▲ growth arrest and DNA damage-inducible protein GADD45 beta apoptosis
HBP1   ▲ HMG box-containing protein 1 cell cycle
ING5 ▼ inhibitor of growth protein 5 DNA metabolic / repair
INSIG2 ▲ insulin-induced gene 2 protein ER-nuclear signaling
KLF7    ▲ Krueppel-like factor 7 cell morphogenisis
MPHOSPH6   ▼ M-phase phosphoprotein 6 cell cycle
NNMT    ▲ nicotinamide N-methyltransferase N-methyltransferase
P4HA1    ▲ prolyl 4-hydroxylase subunit alpha-1 isoform 1 precursor metabolic processes
P4HA2 ▲ prolyl 4-hydroxylase subunit alpha-2 isoform 1 precursor metabolic processes
PLAUR   ▲ urokinase plasminogen activator surface receptor isoform 3 precursor metabolic processes
RHOU   ▲ rho-related GTP-binding protein RhoU cell cycle
TMCC1 ▲ transmembrane and coiled-coil domains protein 1 isoform a transmembrane signaling
UBE2H ▲ ubiquitin-conjugating enzyme E2 H isoform 1 proteolysis
ULBP2 ▲ NKG2D ligand 2 precursor transmembrane signaling
XIAP/BIRC4 ▲ baculoviral IAP repeat-containing protein 4 apoptosis
TP53 NA tumor protein p53 apoptosis/cell cycle
Used for CCHS






Table 3
AMC-AJCC-II
All patients Stage II Stage III
Patient number 126 71 55 90
Age (median) (yrs) 71.2 70 72.9 73.4
   Min (yrs) 35.9 35.9 38.8 34.6
   Max (yrs) 92.9 92.9 86.2 95.1
Sex
   Male 67 (53%) 34 (48%) 33 (60%) 42 (47%)
   Female 59 (47%) 37 (52%) 22 (40%) 48 (53%)
Localisation
   Right sided tumor 63 (50%) 39 (55%) 24 (43,5%) 48 (53%)
   Left sided tumor 63 (50%) 32 (45%) 31 (56,5%) 42 (47%)
T-stage NA
   T2 4 (3%) 0 (0%) 4 (7%)
   T3 109 (86,5%) 67 (94%) 42 (76,5%)
   T4 13 (10,5%) 4 (6%) 9 (16,4%)
N-stage NA
   N0 71 (56%) 71 (100%) 0 (0%)
   N1 39 (31%) 0 (0%) 39 (71%)
   N2 16 (13%) 0 (0%) 16 (29%)
AJCC stage
   II 71 (56%) 71 (100%) 0 (0%) 90 (100%)
   III 55 (44%) 0 (0%) 55 (100%) 0 (0%)
Mucinous type NA
   Yes 36 (29%) 22 (31%) 41 (74,5%)
   No 90 (71%) 49 (69%) 14 (25,5%)
Differentiation NA
   Good 14 (11%) 7 (10%) 7 (13%)
   Moderate 63 (50%) 40 (56,5%) 23 (42%)
   Poor 45 (36%) 20 (28%) 25 (45%)
   Undifferentiated 1 (1%) 1 (1,5%) 0 (0%)
   Not available 3 (2%) 3 (4%) 0 (0%)
Leuven Cohort
Peritoneal invasion NA
   Yes 1 (1%) 1 (1%) 0 (0%)
   No 125 (99%) 70 (99%) 55 (100%)
Extramural venous invasion NA
   Yes 36 (28,6%) 11 (15%) 25 (45%)
   No 81 (64,3%) 59 (84%) 22 (40%)
   NA 9 (7,1%) 1 (1%) 8 (15%)
Resection margin NA
   Positive 1 (1%) 0 (0%) 1 (2%)
   Negative 124 (98%) 71 (100%) 53 (96%)
   NA 1 (1%) 0 (0%) 1 (2%)
Bowel perforation NA
   Yes 5 (4%) 3 (4%) 2 (4%)
   No 121 (96%) 68 (96%) 53 (96%)
Examined lymph nodes NA
   12 or more 83 (66%) 49 (69%) 34 (62%)
   Less than 12 42 (33%) 22 (31%) 20 (36%)
   NA 1 (1%) 0 (0%) 1 (2%)
Adjuvant chemotherapy NA
   Yes 63 (50%) 50 (70,4%) 42 (76,5%)
   No 63 (50%) 21 (29,6%) 13 (23,5%)
Relapse
   Yes 35 (28%) 12 (17%) 23 (42%) 19 (21%)
   No 91 (72%) 59 (83%) 32 (58%) 71 (79%)
Median FU (months) 45.42 49.14 23.1 39.3
   Min (months) 1.3 1.3 1.5 1.6
   Max (months) 76.4 76.4 73.9 120
Table 4
Lower Upper Lower
Age 0.03 0.070 1.03 1.00 1.07
Location (left vs right) 0.13 0.701 1.14 0.59 2.21
Stage (III vs II) 1.23 0.001 3.41 1.69 6.86 0.95 0.017 2.58 1.19
Peritoneal invasion (yes vs no) 1.30 0.203 3.66 0.50 26.89
Extramural venous invasion (yes vs no) 1.60 < 0,001 4.95 2.43 10.07 1.17 0.003 3.21 1.50
Resection margin (positive vs negative) 1.47 0.149 4.36 0.59 32.24
Bowel perforation (yes vs no) 0.70 0.336 2.02 0.48 8.45
Mucinous type (yes vs no) -0.27 0.506 0.76 0.35 1.68
Differentiation 0.856
  Differentiation (moderate vs good) 0.38 0.541 1.46 0.43 4.97
  Differentiation (poor vs good) 0.66 0.296 1.94 0.56 6.77
Adjuvant chemotherapy (yes vs no) 0.19 0.587 1.20 0.62 2.35
Colon Cancer Hypoxia Score (high vs low) 0.91 0.008 2.49 1.27 4.86 0.95 0.013 2.58 1.23
Lymph nodes examined (12 or more vs less than 12) -0.73 0.034 0.48 0.25 0.95 -0.40 0.283 0.67 0.33
 
Beta 
coefficient p-value
Hazard 
Ratio
95,0% CI
Univariate Cox regression analysis
95,0% CI
Multivariate Cox regression analysis
Beta 
coefficient p-value
Hazard 
Ratio
Upper
5.61
6.89
5.43
1.39
95,0% CI
Multivariate Cox regression analysis
Smith VMC
Recurrence
55 patients
Jorissen
MSI
74 patients
Aronow
Recurrence
100 patients
In vitro hypoxia
CaCo2
923 genes
Global test
923 genes
p = 0.0107
Global test
923 genes
P < 0.0001
Global test
923 genes
p = 0.00028
338 genes
with z-score >1
530 genes
with z-score >1
360 genes
with z-score >1
191 351
83
75
51 21
Smith (VMC) Jorissen
21 gene signature
+ TP53
205
Aronow
 
Smith MCC
AJCC stage
177 patients
Backward Regression
Colon Cancer Hypoxia Score
1,301 + 0,543 x [BCCIP] - 0,416 x [BNIP3L] + 0,596 x 
[GADD45B] + 0,538 x [INSIG2] - [MPHOSPH6] - 0,177 x [TP53]
Figure 1
162 stage II/III colon cancer
patients were included
5 (3%) patients were excluded for clinical reasons:
- 1 patient had 2 colon carcinomas
- 3 patients died within one month after surgery
- 1 patient was peroperatively diagnosed with stage IV disease
RNA was extracted in 157 
patients
28 (18%) samples failed quality control
Tissue of 129 patients was 
analyzed by nCounter
Technical failure in 3 (2%) patients
126 patients were successfully
analyzed
Figure 2
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